Solu Therapeutics
PrivateLast Round
Series A
Apr 9, 2025
Est. Valuation
$100M
Total Funding Raised
$72M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Solu Therapeutics is a biotechnology company that develops a cytotoxicity-targeting chimera platform designed to eliminate disease-driving cells, providing oncology therapeutics that help reduce the risk of inflammatory and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Solu Therapeutics Comparables
Compare Solu Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Taran Therapeutics, Inc. | 83% | |
| Immune-Onc Therapeutics | 76% | |
| OncoPrecision | 74% |
Solu Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 9, 2025 | ||||
| Seed | Aug 1, 2023 |
Key People
Founding team and executive leadership
Solu Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hengdian Group Capital | Series A |
| A. M. Pappas & Associates | Series A |
| DCVC Bio | Series A, Seed |
| Santé Ventures | Series A, Seed |
| Alexandria Venture Investments | Series A, Seed |
| Astellas Venture Management | Series A, Seed |
| The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP) | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 20, 2026
Monthly visitors increased 53% MoM.
- Jun 16, 2025
Enda Moran appointed as the new Chief Operating Officer.
Solu Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Solu Therapeutics's valuation, stock price, and market status.
Is Solu Therapeutics a public or private company?
Solu Therapeutics is a private company.
What is the current stock price of Solu Therapeutics?
Solu Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Solu Therapeutics worth (valuation)?
Valuation information for Solu Therapeutics is not publicly available.
Can I buy Solu Therapeutics stock?
Solu Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Solu Therapeutics's last funding round?
Solu Therapeutics's most recent funding round was Series A on April 9, 2025.
Who are the main investors in Solu Therapeutics?
Key investors in Solu Therapeutics include Longwood Fund, Santé Ventures.
Will Solu Therapeutics IPO soon?
No public IPO plans have been announced for Solu Therapeutics.
How can I track Solu Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Solu Therapeutics's secondary market activity and sign up for updates.